{"id":"W2539531174","doi":"10.1016/j.jtho.2016.09.008","title":"ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005737328,0.0003807095,0.0009936151,0.0003020706,0.0002495814,0.001198884,0.0006179555,0.0008316043,0.008694057],"category_scores_gemma":[0.0007180804,0.0002401711,0.0007961201,0.0002378536,0.0003742103,0.0005956733,0.0002364995,0.002244061,0.0014543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009784824,"about_ca_system_score_gemma":0.001050508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0012248,"about_ca_topic_score_gemma":0.002901172,"domain_scores_codex":[0.9997948,0.00005039427,0.00001480771,0.00004081559,0.00003798402,0.0000612454],"domain_scores_gemma":[0.9997167,0.00005935214,0.00005673508,0.00003422168,0.00002061399,0.0001123576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2442593,0.01631909,0.01318404,0.00151641,0.001510375,0.0005696276,0.0001928562,0.002421005,0.08255983,0.001070862,0.02258428,0.6138123],"study_design_scores_gemma":[0.3186987,0.3855056,0.1174213,0.000476979,0.004086272,0.003482085,0.0003121385,0.01188709,0.08702356,0.0009625887,0.06990495,0.0002386275],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878457,0.004178829,0.0002078994,0.000758819,0.0002515799,0.0001882475,0.00153343,0.0002153899,0.004820149],"genre_scores_gemma":[0.9919991,0.001309967,0.0002745883,0.0005487418,0.0001176044,0.00009789356,0.001548781,0.00004124601,0.004062166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008694057,"threshold_uncertainty_score":0.0290845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02788488996954369,"score_gpt":0.4143932316611167,"score_spread":0.3865083416915731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}